ARKG Holdings of Verve Therapeutics (VERV) - Updated Daily
Gene TherapyGenomicsCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 2.02% | $1.01b |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 18 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 35 | $37.81 |
| 🎫ARK Ownership Percent | |
| 4.37% | |
| Description | |
|---|---|
| verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts. | |
| Website | |
| vervetx.com |
Other ETFs That Hold VERV
Research Notes and Commentary for VERV
No Research Notes Found for VERV